Stand E23-6

2019 Edition



Mi-mAbs is an innovative integrated immunotechnology (a consortium) center designed to accelerate the development of new immunotherapy antibodies (mAbs, ADC, Bi-specifics) against cancer and inflammatory diseases.
Open to the best targets of academic and industrial research, MI-mAbs generates antibodies and validates them. MI-mAbs, a multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry , and in vitro / in vivo immunopharmacology.

Scroll to Top
  • No products in the cart.